Predictive diagnostics company specialising in proteomics-based blood tests including PromarkerD for diabetic kidney disease
No capital raise or buyback data
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Historical delivery and spending consistency — data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| US PromarkerD revenue ramp (CMS reimbursement live Jan 2026) | commercial milestone | Confirmed | arrow_upwardHigh | 30 June 2026 | Upcoming |
| PromarkerEndo Australian commercial launch | regulatory decision | Expected | removeMed | 30 June 2026 | Upcoming |
| Oxford University PromarkerEndo cohort (~600 samples) results | data readout | Expected | removeMed | 31 Dec 2026 | Upcoming |
| PromarkerD T1D clinical validation completion | data readout | Expected | removeMed | 31 Dec 2026 | Upcoming |